100 Migraine Drugs, A to Z: prochlorperazine

June 27, 2020

Prochlorperazine (Compazine) belongs to the category of phenothiazine drugs. Chlorpromazine (Thorazine) was the first drug in this family and it was approved for the treatment of schizophrenia in 1950. Phenothiazine drugs have also been found to be effective for the treatment of nausea and vomiting, severe anxiety, and persistent hiccups.

Prochlorperazine is mostly used for the treatment of nausea and vomiting and it is available in tablets, rectal suppositories, and injections. Prochlorperazine appears to be an effective drug not only for the treatment of nausea and vomiting of migraine, but also for head pain and other symptoms.

Prochlorperazine was found to be more effective in treating all migraine symptoms than another antiemetic (nausea drug), metoclopramide (Reglan). In a study of children with migraine seen in an emergency department, intravenous prochlorperazine was more effective than an intravenous pain medication ketorolac (Toradol).

The main side effect of prochlorperazine is restlessness or akathisia, which occurs in a large minority of patients who receive it intravenously. In many patients this symptom is mild but in some, it is severe and extremely unpleasant. Many describe the sensation as if wanting to crawl out of their skin. With regular long-term intake of phenothiazine medications, involuntary movements can be a very serious side effect.

I do have patients for whom chlorpromazine works exceptionally well and with no side effects. Most of them need it not more than a few times a month and most use tablets and less often, suppositories. Suppositories work faster than tablets and are preferred by patients who experience vomiting with their migraines. I also use it occasionally as an intravenous injection in the office when a patient is known to respond to it well or when ondansetron (Zofran), a safer antiemetic, is ineffective.

Written by
Alexander Mauskop, MD
Continue reading
August 8, 2026
Sugar is bad for your brain, even before you are born.
Sugar consumed in the first two years of life increases the risk of dementia.
Read article
August 6, 2026
Research
An Old Medicine that Could Make Brain Stimulation Work Better for Depression and Other Neurological Conditions
A 2022 clinical trial from the University of Calgary found that adding low‑dose D‑cycloserine (DCS), a partial NMDA‑receptor agonist, to intermittent theta‑burst stimulation (iTBS) significantly increased response and remission rates in depression without serious side effects. Early follow‑up data suggest that timing, dose, and drug levels matter, and raise the possibility that this DCS‑TMS approach could eventually be applied to other neurological conditions—such as migraine, postconcussion syndrome, brain fog, and long COVID
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe